Immuron Ltd Files February 2025 6-K Report

Ticker: IMRN · Form: 6-K · Filed: Feb 19, 2025 · CIK: 1660046

Immuron LTD 6-K Filing Summary
FieldDetail
CompanyImmuron LTD (IMRN)
Form Type6-K
Filed DateFeb 19, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, disclosure

Related Tickers: IMRN

TL;DR

Immuron Ltd (IMRN) filed its Feb 2025 6-K, check the announcements for updates.

AI Summary

Immuron Limited, a pharmaceutical company, filed a Form 6-K on February 19, 2025, reporting on its activities for February 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The report details one announcement published by the company during the month.

Why It Matters

This filing provides an update on Immuron Ltd's recent corporate activities and disclosures as a foreign private issuer, which is important for investors tracking the company's compliance and reporting.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain significant new financial or operational information that would immediately impact risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of a Form 6-K filing for Immuron Limited?

A Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country, file with a stock exchange, or distribute to its security holders.

Which form does Immuron Limited indicate it will use for its annual reports?

Immuron Limited indicates it will file annual reports under cover of Form 20-F.

What is Immuron Limited's principal executive office address?

Immuron Limited's principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.

What is Immuron Limited's SIC code?

Immuron Limited's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Does Immuron Limited furnish information to the Commission pursuant to Rule 12g3-2(b)?

No, Immuron Limited has indicated 'No' by check mark for furnishing information pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 19, 2025 regarding Immuron Ltd (IMRN).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing